Diagnostic Suspicion of Primitive Syndrome Sjögren's : Brest Cohort

See also
Status	Clinical Trial	Phase
Completed	`NCT05269810` - Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome	Phase 2
Completed	`NCT01782235` - Efficacy of Tocilizumab in Primary Sjögren's Syndrome.	Phase 2/Phase 3
Recruiting	`NCT05113004` - New Clinical End-points in Patients With Primary Sjögren's Syndrome	Phase 2

See also

Status

Clinical Trial

Phase

Completed

NCT05269810 - Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome

Phase 2

Completed

NCT01782235 - Efficacy of Tocilizumab in Primary Sjögren's Syndrome.

Phase 2/Phase 3

Recruiting

NCT05113004 - New Clinical End-points in Patients With Primary Sjögren's Syndrome

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03681964
Study type	Observational
Source	University Hospital, Brest
Contact	Valerie Devauchelle, MD,PhD
Phone	33 (0) 2 98 34 72 64
Email	valerie.devauchelle-pensec@chu-brest.fr
Status	Recruiting
Phase
Start date	September 28, 2015
Completion date	September 28, 2030

Diagnostic Suspicion of Primitive Syndrome Sjögren's : Brest Cohort — DIApSS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms